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Abstract 
Background: Leishmaniases are a group of neglected tropical parasitic diseases, mainly affecting vulnerable populations 
of countries with poor socioeconomic status. Development of efficient vaccines is a priority due to the increasing incidence 
of drug resistance and toxicity to current treatments. In the search for a safe and efficient protective vaccine for human and 
dog visceral leishmaniases, we analyzed the suitability of the immunomodulatory drug sirolimus (SIR) to boost a preventive 
DNA vaccine against leishmaniasis. SIR is an already marketed drug that has been described to boost immune protection 
against different disease models and has also emerged as a promising therapeutic drug against L. major.
Methods: Syrian hamsters were treated with SIR concomitantly with the administration of a DNA vaccine formula‑
tion consisting in four plasmids carrying the Leishmania genes LACK, TRYP, PAPLE22 and KMPII, respectively. Two weeks 
after the last vaccination, the animals were infected intraperitoneally with L. infantum parasites. Five weeks post‑
infection the parasite load was measured by real‑time PCR in target tissues and immune response was evaluated by 
determining anti‑Leishmania specific antibodies in combination with cytokine expression in the spleen.
Results: Our results show that the DNA vaccine itself efficiently reduced the burden of parasites in the skin (P = 
0.0004) and lymph nodes (P = 0.0452). SIR administration also enhanced the protection by reducing the parasite load 
in the spleen (P = 0.0004). Vaccinated animals with or without SIR co‑treatment showed lower IFN‑γ expression levels 
than those found in the spleen of control animals. mRNA expression levels of NOS2 and IL‑10 were found to be signifi‑
cantly higher in the vaccinated plus SIR treated group.
Conclusions: Co‑administration of SIR enhances a DNA vaccination regimen against L. infantum, improving the 
reduction of parasite load in skin, lymph node and spleen. The analysis of immune markers in the spleen after chal‑
lenge suggests that the trend to recover naïve levels of IFN‑γ and IL‑10, and the concurrent higher expression of 
NOS2, may be responsible for the protection induced by our vaccine co‑administered with SIR.
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Background
Leishmaniasis is a neglected disease caused by pro-
tozoan parasites belonging to the genus Leishmania. 
Transmitted by infected female sand fly vectors, Leish-
mania spp. are responsible for over 1,500,000 human 
cases, resulting in more than 20,000 deaths per year, with 
the highest impact on the poorest people in developing 
countries [1]. Visceral leishmaniasis (VL), also known as 
kala-azar, is the most severe clinical form, resulting in a 
fatal outcome if left untreated [2]. Leishmania infantum 
is the causative agent of zoonotic VL in the Neotropical 
zone and in the Mediterranean Basin, with dogs playing 
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an important role as peridomestic reservoirs and increas-
ing the risk of infection of susceptible human populations 
co-habiting in the same area [3].
Protective immunity against Leishmania is medi-
ated by both innate and adaptive immune responses. 
Thus, today we know that the effective activation of 
macrophages, dendritic cells (DCs), and antigen-spe-
cific CD4+ and CD8+ T cells are all needed to control 
the spread of Leishmania [4]. The immune response 
induced by Leishmania has been fully described in 
the mouse model, with a CD4+ Th1 response (IFN-γ 
and TNF-α secretion) leading to the resolution of the 
disease and protection, and a CD4+ Th2 responses 
(IL-10 and IL-4) being associated with disease pathol-
ogy [5]. CD4+ Th1 cells activate CD8+ T cells which 
are required for optimal resistance, providing ben-
eficial cytokines such as IFN-γ and specifically killing 
parasite-infected cells [6, 7]. Unlike experimental VL 
in mice, most infected people develop asymptomatic 
infections, which correlates with the activation of spe-
cific cell-mediated immunity and a Th1-proinflamma-
tory immune response [8]. The active disease, however, 
has been linked to high antibody levels and a progres-
sive Th2-deactivating immune response in the presence 
of a strong inflammatory reaction [9].
In spite of several efficient drugs currently available, in 
many occasions these drugs are of limited access to the 
affected population. On the other hand, the increasing inci-
dence of toxicity cases and drug-resistant leishmaniasis, 
require the development of safe and efficient preventive vac-
cines [10, 11]. Currently, there are three licensed and com-
mercialized vaccines for canine leishmaniases prevention, 
 CaniLeish®, Leish-Tech® and  Letifend® [12–14]. Despite 
several efforts made using experimental models [15], there 
is no licensed vaccine against human leishmaniasis yet.
DNA vaccines are a suitable approach for several rea-
sons, including the ability of plasmid DNA to stimulate Th1 
responses by the presence of CpG motifs [16]. In addition, 
DNA vaccines are safe, have lower production costs, and 
are easy to store because a cold-chain is not required [17]. 
Several DNA vaccination approaches against Leishmania 
have been developed to date, reaching different degrees of 
protection in mice but achieving less immunogenicity in 
more complex models [18]. Thus, the co-administration 
of immunomodulatory compounds may be of paramount 
importance to boost the immune response induced by 
DNA vaccines. For this purpose, many adjuvants have been 
used in different Leishmania-vaccine trials [19], but phys-
icochemical incompatibilities and undesirable adverse reac-
tions remain a major problem (reviewed in [20]).
Sirolimus (SIR), also known as rapamycin, is an immu-
nosuppressant drug which is licensed and marketed pri-
marily to prevent organ transplant rejection [21, 22]. 
SIR acts by binding and constraining the activity of the 
mechanistic (mammalian) target of rapamycin (mTOR), 
a highly conserved pathway among eukaryotic organ-
isms that orchestrates cell adaptations to environmental 
changes by controlling cell survival strategies, cell prolif-
eration and metabolic adaptations at the transcriptional 
and translational levels [23]. Recent studies have opened 
a whole new field of research by showing that SIR admin-
istration during the expansion and contraction phase of 
a primary immune response results in an increased mag-
nitude and quality of CD8+ T memory cells [24]. SIR 
administration has shown promising adjuvant results on 
different vaccine trials against viruses [25, 26], cancer 
models [27, 28] and even against intracellular mycobac-
teria infection [29]. The protection achieved using SIR 
in these studies of vaccination was mediated by the gen-
eration of memory effector CD8+ T and the concurrent 
increase in IFN-γ production. In regards to Leishmania, a 
recent study using SIR as a therapeutic agent on a mouse 
model of cutaneous leishmaniasis showed promising 
results, pointing that this molecule could be a potential 
candidate for further research in the field of leishmaniasis 
[30].
We have previously studied the effect of a DNA vaccine 
carrying the Leishmania genes LACK, TRYP, PAPLE22 
and KMPII in a hamster model of leishmaniasis. When 
administered alone, it was poorly immunogenic but 
induced partial protection when followed by a protein 
vaccine boost [31]. The aim of the present study was to 
test in hamsters if the co-administration of SIR would 




The L. infantum strain MCAN/ES/92/BCN83 (zym-
odeme MON-1) was kindly provided by Dr Montserrat 
Portús, Universitat de Barcelona, Spain. It was obtained 
from a naturally infected and untreated dog and main-
tained through hamster passages to retain its full viru-
lence. Hamsters were intraperitoneally infected with 
stationary promastigotes, and at 3 months post-infection, 
parasites were isolated from spleen samples incubated in 
R15 medium (RPMI 1640 medium (Gibco, Billings, USA) 
supplemented with 15% heat-inactivated fetal calf serum 
(Gibco), 1 M 2% HEPES (Gibco) and 1% of total volume 
of 10,000 U/ml penicillin, and 10,000 μg/ml streptomycin 
(Gibco)).
Promastigotes were maintained at 26 °C in R15 
medium, and weekly passages were performed. A second 
passage of Leishmania infantum cultures at stationary 
growth (6-day culture) was used for infection to assure 
than > 85% of promastigotes were metacyclic and that 
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virulence was retained [32]. Stationary promastigotes for 
infection were washed and resuspended in PBS at 1 ×  107 
parasites/ml.
Animals
Thirty-four male, 7-week-old, Syrian golden hamsters 
(Mesocricetus auratus, strain RjHAN-AURA) were 
obtained from Centre d’Elevage René Janvier (Le Genest-
Saint-Isle, France). The animals were kept individually 
in plastic microfilter cages under BSL2 conditions at the 
Servei d’Estabulari of Universitat Autònoma de Barcelona 
(Barcelona, Spain), and food and water were provided ad 
libitum. The study comprised a large experiment with 
30 hamsters randomly distributed into 3 experimental 
groups of 10 animals each: treated with SIR and DNA 
vaccinated group (S +  V); DNA-vaccinated group (V); 
and PBS-inoculated control group (C). The 30 hamsters 
were further infected with Leishmania infantum (see 
below) and four additional hamsters were used as a non-
infected control group (NI).
Sirolimus treatment
Rapamune® (sirolimus 1 mg/ml) was purchased from 
Pfizer (New York, USA) and kept under conditions speci-
fied by the manufacturer. Treatment doses of 0.075 mg/
kg in 500 μl of PBS were prepared daily under asep-
tic conditions [24]. The S  +  V group received a daily 
intraperitoneal dose from day − 1 (one day prior to the 
first vaccination) for 6 consecutive weeks. The V and C 
groups of hamsters were handled under the same condi-
tions and were PBS-inoculated.
Immunization
The open reading frames (ORF) from L. infantum genes 
TRYP (GenBank: AF044679), PAPLE22 (GenBank: 
AF123892), LACK (GenBank: U49695) and KMPII (Gen-
Bank: X95267) were individually cloned into a pVAX 1 
vector (Invitrogen, Waltham, USA) as described else-
where [18, 31]. Each DNA construction was purified 
using EndoFree Plasmid Maxi Kit (Qiagen, Venlo, Neth-
erlands) according to the manufacturer’s instructions. 
The immunogenicity of these plasmids was previously 
tested [31].
Each hamster received three doses (2 weeks apart) of 
100 µg of each plasmid administered intramuscularly into 
their hind limb (V and S +  V groups). To maintain the 
same handling conditions, the C group was injected with 
physiological saline solution.
Infection
Two weeks after the administration of the last vaccine 
dose, all animals but the NI group were intraperitoneally 
inoculated with 1 ml of PBS containing 1 ×  107 L. infan-
tum metacyclic promastigotes. Animal weight and typical 
VL clinical signs in the rodent model, i.e. hair and weight 
loss, and cutaneous lesions, were weekly evaluated.
Necropsy and sample collection
All animals (n = 34) were euthanized at 5 weeks post-
challenge (Fig. 1). Hamsters were anesthetized with a 100 
μl intramuscular injection containing ketamine (42.8 mg/
kg), acepromazine (1.4 mg/kg) and xylazine (9.5 mg/kg). 
An intracardiac puncture was performed to obtain 5 ml 
Fig. 1 Graphical representation of the experimental assay. The study comprised a large experiment with a total of 34 Syrian golden hamsters 
randomly distributed in 4 groups: NI (non‑infected group, n = 4), C (PBS‑inoculated control group, n = 10), V (DNA vaccinated group, n = 10), and 
S + V (sirolimus‑treated and DNA vaccinated group, n = 10). Hamsters received sirolimus or a PBS solution daily from one day prior to the first 
vaccination for 6 consecutive weeks. Three vaccine doses were administered, leaving a 2‑week period between them. C, V and S + V animals were 
challenged two weeks after receiving the last vaccination dose and all hamsters were sacrificed 5 weeks later
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of blood sample from each animal, and the animals were 
then euthanized in a  CO2 chamber. Samples of spleen, 
liver, submandibular lymph nodes (LN) and healthy pin-
nae skin from each hamster were aseptically obtained 
and kept on ice to avoid tissue degradation.
Evaluation of humoral immune response: total hamster 
IgG anti‑L. infantum
Blood samples were collected at the end of the study in 
hematology crystal tubes (BD  Vacutainer®; BD, New Jer-
sey, USA) and centrifuged at 2000×g for 15 min to obtain 
serum samples and were frozen until analyzed. ELISA 
plates (Costar high binding transparent flat bottom; Fisher 
Scientific, Waltham, USA) were coated overnight at 4 °C 
with 2 µg per well of Crude Total Leishmania Antigen 
(CTLA) in 100 µl of carbonate-bicarbonate coating buffer 
(0.1 M  NaCO3-H2CO3 pH 9.6). CTLA was provided by Dr 
Cristina Riera, Universitat de Barcelona, Spain. Samples 
were diluted 1:400 in PBS with 0.05% Tween 20 and 1% 
skimmed milk powder (PBSTM) and serially diluted in the 
pre-coated plate. Plates were incubated at 37 °C in a humid 
atmosphere for 1 h and were then washed 3 times with 
PBST and once with PBS. Plates were then incubated for 
1 h at 37 °C with goat anti-hamster IgG-HRPO (Bio-Rad, 
Hercules, USA) diluted 1:1000 in PBSTM. Antibody excess 
was removed with another cycle of washes as described 
above. Then, 100 µl of the peroxidase substrate tetrameth-
ylbenzidine (TMB) (Sigma-Aldrich, St. Louis, USA) was 
added to each well, and the plates were left to develop for 
5 min. The reaction was stopped by the addition of 50 µl of 
1 M  H2SO4, and the absorbance was recorded at 450 nm 
(Anthos 2001 reader; Anthos Labtech instruments, Wals, 
Austria). The cut-off value was set as the average opti-
cal densities (ODs) of NI serum samples plus 3 times the 
standard deviation (cut-off = 0.015 OD).
DNA extraction and real‑time PCR absolute parasite 
quantification
The efficacy of the vaccination strategies was evaluated 
by measuring the parasite reduction in target organs 
[33, 34]. Total genomic DNA was obtained from 50 mg 
of spleen, liver, skin and LN samples of the study ani-
mals by using the High Pure Template Preparation Kit 
(Roche, Basel, Switzerland) following the mouse tail pro-
tocol provided in the manufacturer’s guidelines. DNA 
concentration was measured using a NanoDrop 2000 
Spectrophotometer (Isogen Life Science, De Meern, The 
Netherlands). All DNA samples were kept at −  20 °C 
until the qPCR was performed.
Primers targeting conserved DNA regions of the 
kinetoplast minicircle DNA from L. infantum and 
TaqMan-MGB probes were used as formerly described 
[35] (Table 1). Triplicates of 25 ng of DNA of each sam-
ple, a negative control using nuclease-free water (Sigma-
Aldrich) instead of DNA, and a standard curve were run 
in an Applied Biosystems StepOnePlus™ PCR instrument 
(Applied Biosystems, Waltham, USA) following a thermal 
cycling profile of 50 °C for 2 min, 95 °C for 10 min, 40 
cycles at 95 °C for 15 s, and 60 °C for 1 min. The resulting 
data were analyzed using StepOnePlus™ software v2.3 
(Applied Biosystems). The number of parasites per µg of 
DNA was calculated by interpolation to a standard curve 
generated by using a 10-fold serial dilution from  103 to 
 10−3 promastigotes of a L. infantum culture (y = − 3.38x 
+ 28.43). The median qPCR efficiency (99%), and slope 
(−  3.38) were calculated from three different replicates. 
Parasite quantification was linear between  103 and  10−2 
parasites per sample (R2 = 0.993).
Cytokine determination
Cytokine expression of all groups (n = 34) was stud-
ied in spleen tissue. Samples maintained in RNAlater 
(Ambion, Austin, USA) were homogenized with TRI 
Reagent (Ambion) and kept frozen until RNA extrac-
tion. Total RNA was extracted by using the RiboPure 
kit (Ambion) following the manufacturer’s instruc-
tions, and samples were then treated with DNases 
TURBO-DNA free kit (Ambion). Clean RNA samples 
were stored at −  80 °C until analyzed. Retrotranscrip-
tion was carried out by using the High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) fol-
lowing a thermal profile of 25 °C for 10 min, 37 °C for 
120 min, and 95 °C for 5 min. Levels of IFN-γ, FoxP3, 
TNF-α, IL-10, IL-21, NOS2 and TGF-β expression were 
determined in addition to RPL18 as a control gene to 
calculate relative gene expression levels [36]. To ensure 
amplification of cDNA sequences derived from the ret-
rotranscription of the mRNAs of interest, primers were 
designed including exon boundary sequences based on 
basic primer information extracted and modified from 
Zivcec et  al. [36] and Espitia et  al. [37] (Table  2). Rat 
(Rattus norvergicus) sequences were used for exon-
boundary area determination, as hamster sequences are 
Table 1 Sequence of primers and probe used for parasite 
detection [35]
Abbreviations: F, forward primer; R, reverse primer; P, probe
Gene Primer sequence (5ʹ‑3ʹ)
Kinetoplastid minicircle DNA F AAC TTT TCT GGT CCT CCG GGTAG 
R ACC CCC AGT TTC CCGCC 
P FAM–AAA AAT GGG TGC AGA AAT –MGB
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not available for ENSEMBL analysis [38], and previous 
BLAST and CLUSTALW analyses confirmed sequence 
identity. Amplification of each sample was carried 
out in triplicate using SYBR select RT-PCR Master 
Mix Reagents (Applied Biosystems) with the aid of an 
Applied Biosystems StepOnePlus™ PCR instrument 
and StepOnePlus™ Software v2.3 (Applied Biosystems). 
The thermal cycling profile was 10 min at 50 °C, fol-
lowed by 40 cycles of 95 °C for 10 min, 95 °C for 15 s, 
and 60 °C for 1 min. Melting curves assessed the speci-
ficity of our amplification products. Cytokine mRNA 
expression levels were normalized to the expression 
levels of the housekeeping gene RPL18. Fold induction 
levels were calculated by using the median values of the 
C group.
Statistical analysis
Exploratory data analysis and inference were carried 
out by using R statistical software v3.2.5 [39]. Differ-
ences among groups were analyzed using robust one-
way ANOVA with corresponding pairwise post-hoc 
tests included in the WRS2 package v0.4-0 [40, 41]. The 




Animals from group V showed a reduction in the num-
ber of parasites compared to group C in the skin (mean 
reduction of 60%; ψ̂ = 94.14, 95% Confidence Interval (CI): 
36.41–180.64, P = 0.0004) and LN (mean reduction of 83%; 
ψ̂ = 1.04, 95% CI: 0.13–2.05, P = 0.0452). Non-significant 
differences were observed in the liver (mean reduction of 
78%; ψ̂ = 886.28, 95% CI: −  6.26–1902.01, P = 0.1072) 
and spleen (mean reduction of 4%; ψ̂ = 48.41, 95% CI: 
− 222.59–286.74, P = 0.8372).
Compared to group C, animals in the S + V group also 
had reduced numbers of parasites in skin (mean reduc-
tion of 79%; ψ̂ = 80.75, 95% CI: 11.03–152.33, P = 0.0400) 
and LN (mean reduction of 83%; ψ̂ = 0.95, 95% CI: 0.09–
2.03, P = 0.0489), together with a significant protection in 
the spleen (mean reduction of 32%; ψ̂ = 369.79, 95% CI: 
180.09–561.06, P = 0.0004), with parasite burdens concur-
rently lower than group V (mean reduction of 57%; ψ̂ = 
321.37, 95% CI: 125.36–551.69, P = 0.0080). Although non-
statistically significant ( ̂ψ = 936.50, 95% CI: 44.63–1945.62, 
P = 0.0598), there was also a noticeable trend of burden 
reduction in the livers of hamsters of the S + V group com-
pared to group C (mean reduction of 81%) (Fig. 2).
Analysis of the immune response
Anti‑Leishmania IgG production
All infected hamsters seroconverted and had IgG antibod-
ies against CTLA at the time of sacrifice, 5 weeks post-
infection (IgG cut-off = 0.015 OD). Leishmania-specific 
IgG production was reduced in group V animals when 
compared to group C ( ̂ψ = 0.12, 95% CI: 0.02–0.22, P = 
0.0475), and S + V ( ̂ψ = − 0.12, 95% CI: − 0.22–0.04, P 
= 0.0180). In contrast, similar levels of Leishmania-specific 
antibodies were detected between groups S  +  V and C 
(Fig. 3).
Cytokine and immune markers production
Expression of cytokines (IFN-γ, TNF-α, IL-10, IL-21 and 
TGF-β) plus the Treg immune marker FoxP3, and the 
NOS2 enzyme was studied and detected by the end of the 
Table 2 Sequences of primers used for expressed cytokines 
detection
Note: Data extracted and modified from Espitia et al. [37] and Zivcec et al. [36]
Abbreviations: F, forward primer; R, reverse primer
Gene Primer sequence (5ʹ‑3ʹ)
RPL18 F GTC CCT GTC CCG GAT GAT C
R GAC AGT CCC CAC AAC CAC G
IFN‑γ F CTA TGT CTG GCT GCT ACT GCCA 
R TTC ACG ACA TCT AAG CTA CTT GAG TTAA 
TNF‑α F CCA GAC ACT CAC ACT CAG ATC ATC TT
R CAC TTG GTG GTT TGC TAC AACGT 
TGF‑β F CTA CCA CGC CAA CTT CTG TCTG 
R TGT AGA GGG CAA GGA CCT TACTG 
FoxP3 F CAA GTG GCC TGG TTG TGA GA
R TGA TCT GCT TGG CAG TGC T’
IL‑21 F CCA GCT CCA CAA GAT GTA AAGGA 
R GCT GAC TTG AGT TTG GCC TTCT 
IL‑10 F CAT CGA TTT CTC CCC TGT GAA 
R GAC GCC TTT CTC TTG GAG CTT 
NOS2 F CCA GAA CAG AGG GCT CAA AGG 
R CCT GCA TCT CTT CCC GAT AGAG 
Fig. 2 Leishmania infantum DNA load. qPCR analyses showing the number of parasites detected per μg of DNA extracted from the spleen (a), 
liver (b), lymph node (c) and skin (d) comparing the three Leishmania‑infected studied groups: C (PBS‑inoculated control group, n =10), V (DNA 
vaccinated group, n = 10), and S + V (sirolimus‑treated and DNA vaccinated group, n = 10). Parasite number was calculated by interpolation to a 
standard curve constructed with a L. infantum promastigote culture (e). Abbreviations: Cq, quantification cycle. ANOVA; *P < 0.05, **P < 0.01, ***P < 
0.001
(See figure on next page.)
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study in spleen samples of all experimental groups (n = 34). 
The results are shown in Fig. 4.
First, we compared the non-infected hamsters (NI 
group) versus the PBS control infected animals (group C). 
Leishmania infantum infection (group C) significantly 
increased the expression of IFN-γ mRNAs ( ̂ψ = 80.75, 
95% CI: 11.03–152.33, P = 0.0400), whereas it significantly 
reduced the expression of TNF-α ( ̂ψ = − 842.43, 95% CI: 
− 1466.92–217.95, P = 0.0041), IL-10 ( ̂ψ = 321.38, 95% CI: 
125.36–551.69, P = 0.0080), FoxP3 ( ̂ψ = −  0.34, 95% CI: 
− 0.47–0.19, P < 0.0001), and NOS2 ( ̂ψ = − 1.04, 95% CI: 
− 1.74–0.38, P < 0.0001) mRNAs in the spleen (Fig. 4). The 
transcription profile of V and S + V groups were similar to 
that of group C when they were compared to NI animals. 
IFN-γ was the only exception with levels in vaccinated ani-
mals not statistically different from those of the NI group.
Both vaccinated groups (V and S + V) expressed simi-
lar transcription patterns for the studied molecules with 
higher expression levels of NOS2, IL-10, FoxP3, TGF-β 
and TNF-α, with a concurrent reduction of IFN-γ when 
compared to group C (Fig. 4). Statistical analysis showed 
that the S + V group expressed higher NOS2 (2.12-fold 
increase; ψ̂ = −  1.04, 95% CI: −  1.74–0.38, P = 0.016) 
and IL-10 levels (1.8-fold increase; ψ̂ = − 0.87, 95% CI: 
−  1.33–0.42, P = 0.010) compared with group C. The 
DNA vaccine alone induced an increase in NOS2 and 
IL-10 expression, although not significant, when com-
pared with group C animals. No differences in TNF-α, 
TGF-β and FoxP3 expression were found between any 
vaccinated group and the group C hamsters in the spleen. 
There were trends ( ̂ψ = −  1.04, 95% CI: −  2.51–0.43, 
P = 0.0552) for both vaccinated groups (V and S +  V) 
in reducing IFN-γ expression (0.588- and 0.609-fold, 
respectively) compared to group C (Fig. 4).
Discussion
Previous studies have highlighted the need for finding 
new boosting strategies to potentiate protection induced 
by DNA immunization. Although mTOR inhibitors have 
been used for enhancing protection against some bacte-
rial and viral infections, and very recently in the treat-
ment of cutaneous leishmaniasis [30], nothing is known 
about their effect in a vaccination protocol against VL. 
To the best of our knowledge, the present study repre-
sents the first use of the immunosuppressive drug SIR in 
a vaccination strategy against VL with the aim of improv-
ing the immune response against this parasitic infection.
Naked DNA vaccination reduced L. infantum para-
site loads in the lymph nodes and skin. Our results show 
that administering SIR during immunization along with 
the naked DNA vaccine significantly reduces the parasite 
load even in the spleen, the main Leishmania target organ, 
indicating that SIR treatment can enhance the protection 
provided by the naked DNA vaccine itself. Recently, the 
utilization of SIR as a treatment for L. major cutaneous 
leishmaniasis in mice led to a significant reduction of para-
site burden in draining lymph nodes [30], also confirming 
that the use of mTOR inhibitors could be a new strategy to 
limit the growth of different Leishmania species.
Administering SIR during vaccination results in accelera-
tion of the CD8+ T cell differentiation program towards 
memory cells [24], thus promoting enhanced specific 
immune responses, such as IFN-γ production. Due to the 
Fig. 3 Comparison of anti‑Leishmania IgG levels in group C 
(PBS‑inoculated control group), V (DNA vaccinated group), and 
S + V (sirolimus‑treated and DNA vaccinated group) at 5 weeks 
post‑challenge. Antibody levels were measured by ELISA against 
crude total L. infantum antigen (n = 30). Cut‑off value (mean + 3 SD) 
was set at 0.015 OD. ANOVA; * P < 0.05
Fig. 4 Cytokine expression in spleen samples at the end of the study. IFN‑γ, TNF‑α, NOS2, IL‑10, IL‑21, FOXP3, and TGF‑β expression was determined 
by RT‑qPCR using SYBR Green as the detection chemistry. NI: non‑infected group (n = 4); C: PBS control group (n = 10); V: DNA vaccinated group (n 
= 10); S + V: sirolimus‑treated and DNA vaccinated group (n = 10). NI group was taken as a reference group, with a value of 1. ANOVA; *P < 0.05, **P 
< 0.01, ***P < 0.001**** P < 0.0001
(See figure on next page.)
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lack of reagents available for the hamster model, analy-
sis of isolated CD8+ T cells was not possible. Expression 
analyses of some relevant cytokines involved in VL con-
trol and pathogenesis in spleen tissue were performed to 
characterize the immune response triggered in this organ 
after challenge. Unfortunately, immune response in other 
target organs was not evaluated in the present study and 
future experiments will show if parasite reduction in dif-
ferent tissues caused by SIR and DNA vaccine depends on 
the same immune mechanisms as in the spleen. The pro-
tection observed in S + V animals was associated with a 
significant increase in NOS2 expression in the spleen, an 
indication of adequate anti-parasite effector function. In 
accordance with our results, some studies have shown that 
inhibition of mTORC1 by rapamycin in macrophages acti-
vated the M1 phenotype, characterized by the secretion of 
proinflammatory cytokines, effective parasite killing, and 
increased expression of the NOS2 enzyme [42–44]. Levels 
of NO production and NOS2 expression in hamster mac-
rophages have been associated with Leishmania vaccine 
protection in other studies [45, 46]. Despite the relative 
unresponsiveness of NOS2 transcription to IFN-γ in ham-
sters [47], other cytokines, such as TNF-α, might induce 
NO production in macrophages [48]. However, we did not 
detect a significant increase in TNF-α expression in the 
S + V group, though IL-1, IFN-α, or IFN-β could also be 
implicated in NOS2 expression.
Surprisingly, despite the parasitological protection 
observed in the spleen in SIR-treated hamsters, we found 
a decreasing trend in IFN-γ production in the same tissue, 
suggesting that the mediated protection in our model may 
not be due to the expected SIR effect (increase of IFN-γ 
production), or at least we could not detect it by analyz-
ing the whole spleen at five weeks post-infection. Analy-
sis of immune response before challenge would have been 
very useful to characterize the SIR and vaccination effect 
and future studies will address this important question. 
Another explanation for the unexpected decrease in IFN-γ 
production could be that mTORC1 inhibition enhances 
CD8+ T cell memory development but diminishes CD8+ 
T cell effector function with reduced IFN-γ production 
[49]. SIR administration against L. major infection induced 
enhanced specific IFN-γ production, but the treatment 
schedule and SIR dose were different than those used in 
the present study [30]. Although IFN-γ is a cytokine widely 
accepted to be involved in Leishmania control, it is also 
known to steadily increase during early stages of infection 
without a clear contribution to parasite control [47, 50]. In 
this line, our control infected animals showed higher lev-
els of this cytokine when compared to non-infected con-
trols. Moreover, recent studies have also shown that IFN-γ 
has a paradoxical effect in promoting Leishmania growth 
in macrophages from chronically infected hamsters [51]. 
Consistently, in our study, vaccinated animals presented 
lower IFN-γ expression levels in spleen samples than in 
control hamsters, suggesting that the combined activity of 
sirolimus with our DNA vaccine regulated the overexpres-
sion of IFN-γ, and possibly its counterproductive effect. 
Further studies are needed to investigate the cell source 
of IFN-γ and its role during disease in L. infantum infec-
tion. In addition, measurement of the expression of other 
important cytokines for Leishmania control, such as IL-12, 
could contribute to a better understanding of the protec-
tive effect generated by our vaccine protocol.
Parasitological protection in the spleen of SIR-vacci-
nated animals took place even under high expression 
levels of IL-10. A key role in the pathogenesis of murine 
and human VL is usually assigned to IL-10 [52, 53]. How-
ever, it is worth noting that other authors have shown 
that IL-10 signaling neither influences Th1 responses 
nor is responsible for vaccine failure in a L. major mouse 
model [54]. Conversely, it may play a pivotal role by lim-
iting excess inflammation during infection, as suggested 
for other intracellular pathogens [55, 56]. In our model, 
L. infantum infection (group C) caused a significant 
decrease of this cytokine production with regard to the 
non-infected controls (group NI); in contrast, vaccinated 
animals (V/S + V) showed a slight recovery of IL-10 lev-
els. Other vaccine attempts with L. infantum antigens in 
dogs have also shown mixed pro- and anti-inflammatory 
cytokine environments, with higher IL-10 production 
induced in vaccinated animals [57, 58]. These results sug-
gest that IL-10 might play a beneficial immune regulatory 
role in L. infantum infection.
Other immunoregulatory markers such as IL-21, FoxP3 
and TGF-β showed no significant expression variations 
between vaccinated and infected control group (group C) 
although a tendency of being dysregulated during infec-
tion was detected. In our study, the FoxP3 marker was 
downregulated during infection and presented a ten-
dency to increase in the S + V group. FoxP3+ regulatory 
T cells (Tregs) produce TGF-beta and IL-10 but their 
role in this parasitic disease is still not clear [53]. In this 
regard, IL-21 has an important role amplifying IL-10 pro-
duction by type 1 regulatory T cells (Tr1) in VL patients 
[59]. However, in our study, L. infantum-infected ham-
sters expressed high levels of IL-21 cytokine that did 
not seem correlated with the changes observed in IL-10 
expression. More information is needed to elucidate the 
actual role of Treg and Tr1 cells in VL protection, which 
is becoming essential to the understanding which cells 
are responsible for the observed differences.
Plasmid DNA vaccines are also known to pro-
mote antibody production [16, 60]. However, serol-
ogy levels in our study revealed a significant decrease 
of anti-Leishmania-specific IgG antibodies five weeks 
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post-challenge in hamsters receiving the vaccine alone 
when compared to the group C. These reduced anti-
body levels have already been observed in a previous 
experimental trial of this vaccine and may be explained 
by the capacity of the vaccine to control the aberrant B 
cell differentiation widely associated with disease pro-
gression [31]. Surprisingly, adding SIR to the immu-
nization protocol translated into a significant increase 
in Leishmania-specific IgG levels compared to animals 
receiving the DNA vaccine alone, which were close to 
the control group. An association between increased 
antibody responses due to polyclonal B cell activation, 
elevated parasite burden, and the absence of prolifera-
tive responses, has been described in the VL hamster 
model [61]. However, the increase in Leishmania-spe-
cific IgG levels in animals treated with SIR observed in 
our study was not accompanied by an increase in para-
site burden. SIR administration during an immuniza-
tion assay with influenza virus did not alter specific IgG 
antibody levels compared to infected non-protected 
controls [25]. Detection of specific antibodies against 
each one of the antigen vaccine candidates would be 
needed to further characterize the SIR response.
Conclusions
The co-administration of SIR potentiated the protec-
tion conferred by the DNA vaccine carrying the Leish-
mania genes TRYP, PAPLE22, KMPII and LACK in 
the pVAX vector assayed in this study. The protection 
achieved was associated with enhanced NOS2 expres-
sion accompanied by high IL-10 mRNA levels. The role 
of mTORC1 is complex and immune cell type-depend-
ent [62], therefore, further studies are needed to char-
acterize its role in T-cells and macrophages during L. 
infantum vaccination.
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